Pediatric ID News

Moderna this week said preliminary clinical trial data confirmed that its updated COVID-19 vaccine provides a “significant boost” in neutralizing antibodies against emerging SARS-CoV-2 viruses and is expected to effectively target them.

The AAP published guidance on the use of nirsevimab, recommending it for all infants aged younger than 8 months to prevent severe disease from respiratory syncytial virus.

A national shortage of amoxicillin led to an increase in the use of alternative agents to treat ear infections, according to a study published in Pediatrics.

A study of SARS-CoV-2 transmission in 10 Massachusetts school districts found that the secondary attack rate of SARS-CoV-2 among school contacts was low — between 2% and 3% — and that masking reduced the odds of transmission by almost 90%.

The CDC has recommended that infants be immunized with a monoclonal antibody against respiratory syncytial virus.

Researchers confirmed the dosing of an ART combination designed to treat children with HIV and found that it was safe, well tolerated and efficacious through 24 weeks, according to results published in The Lancet HIV.

This coming fall and winter, older adults in the United States will face a decision: Should they roll up their sleeves to receive the world’s first approved vaccines against respiratory syncytial virus?

One in six toddlers in the United States did not complete the vaccination series for seven recommended childhood vaccines in 2019, the year before the COVID-19 pandemic, according to a study published in Pediatrics.

Infectious diseases physician Jeanne M. Marrazzo, MD, MPH, will be the next director of the National Institute of Allergy and Infectious Diseases, the NIH announced Wednesday.

Croup symptoms improved when children were exposed to 30 minutes of outdoor cold air in addition to receiving a steroid, according to the results of a randomized controlled trial published in Pediatrics.